Harbour BioMed receives FDA IND approval for phase 2 trial and orphan drug designation for HBM9167

02/28/2020/0 Comments/in News /by CAPTIS

Separately, the Agency's Office of Orphan Products Development granted HBM9167 Orphan Drug Designation (ODD) for the use in treating NPC. "Nasopharyngeal cancer is a tumor type for which The post Harbour BioMed receives FDA IND approval for phase 2 trial and orphan drug designation for HBM9167 appeared first on Pharmaceutical Business review.

Read more
https://captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2020-02-28 01:31:132020-02-28 02:31:16Harbour BioMed receives FDA IND approval for phase 2 trial and orphan drug designation for HBM9167

Boehringer Ingelheim enters discovery stage

collaboration with Trutino Biosciences

02/28/2020/0 Comments/in News /by CAPTIS

Under the terms of strategic alliance, Boehringer Ingelheim gains access to Trutino's ODC platform technology for the generation and development of up to three new ODC candidates. This The post Boehringer Ingelheim enters discovery stage collaboration with Trutino Biosciences appeared first on Pharmaceutical Business review.

Read more
https://captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2020-02-28 00:31:032020-02-28 01:31:05Boehringer Ingelheim enters discovery stage collaboration with Trutino Biosciences

GSK, Innoviva seek EMA approval for Trelegy Ellipta to treat asthma in adults

02/27/2020/0 Comments/in News /by CAPTIS

The regulator has accepted the application for the use of once-daily and single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) to treat asthma in adults. Trelegy Ellipta The post GSK, Innoviva seek EMA approval for Trelegy Ellipta to treat asthma in adults appeared first on Pharmaceutical Business review.

Read more
https://captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2020-02-27 23:32:042020-02-28 00:32:06GSK, Innoviva seek EMA approval for

Trelegy Ellipta to treat asthma in adults

FDA advisory committee votes in favour of Lilly's CYRAMZA as first-line treatment for metastatic EGFR-mutated NSCLC

02/27/2020/0 Comments/in News /by CAPTIS

"Given the unmet need that remains in treating metastatic EGFR-mutated non-small cell lung cancer, we are encouraged that the majority of these experts agree CYRAMZA plus erlotinib has The post FDA advisory committee votes in favour of Lilly's CYRAMZA as first-line treatment for metastatic EGFR-mutated NSCLC appeared first on Pharmaceutical Business review.

Read more
https://captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2020-02-27 02:31:302020-02-27 03:31:31FDA advisory committee votes in favour of Lilly's CYRAMZA as first-line treatment for metastatic EGFR-mutated NSCLC

Japan’s Takeda buys PvP Biologics in $330m deal

02/27/2020/0 Comments/in News /by CAPTIS

PvP Biologics has been acquired following the conclusion of Phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062), which is being developed to treat uncontrolled celiac disease. The The post Japan’s Takeda buys PvP Biologics in $330m deal appeared first on Pharmaceutical Business review.

Read more
https://captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2020-02-27 02:01:322020-02-27 03:01:34Japan’s Takeda buys PvP Biologics in $330m deal

Novartis, DNDi to jointly develop LXE408 for visceral leishmaniasis

02/26/2020/0 Comments/in News /by CAPTIS

LXE408 was discovered at Novartis with the financial backing of the Wellcome Trust. According to Novartis, more than a billion people across the world are at risk of The post Novartis, DNDi to jointly develop LXE408 for visceral leishmaniasis appeared first on Pharmaceutical Business review.

Read more
https://captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2020-02-26 03:31:202020-02-26 04:31:22Novartis, DNDi to jointly develop LXE408

for visceral leishmaniasis

AstraZeneca divests global rights to Movantik

02/26/2020/0 Comments/in News /by CAPTIS

Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “This divestment The post AstraZeneca divests global rights to Movantik appeared first on Pharmaceutical Business review.

Read more
https://captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2020-02-26 01:01:092020-02-26 02:01:11AstraZeneca divests global rights to Movantik

Lysogene receives FDA fast track designation for LYS-

SAF302 gene therapy in MPS IIIA

02/26/2020/0 Comments/in News /by CAPTIS

LYS-SAF302, a second-generation gene therapy, is designed to deliver a functional copy of the SGSH (N-sulfoglucosamine sulfohydrolase) gene to the brain through a one-time direct-to-CNS administration, and is The post Lysogene receives FDA fast track designation for LYS-SAF302 gene therapy in MPS IIIA appeared first on Pharmaceutical Business review.

Read more
https://captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2020-02-26 00:01:052020-02-26 01:01:08Lysogene receives FDA fast track designation for LYS-SAF302 gene therapy in MPS IIIA

Genentech, Bicycle Therapeutics sign immuno-oncology therapies deal

02/25/2020/0 Comments/in News /by CAPTIS

Under a strategic collaboration agreement, the companies will involve in the discovery, development and commercialisation of novel Bicycle Therapeutics-based immuno-oncology therapies. The deal allows Bicycle to explore its The post Genentech, Bicycle Therapeutics sign immuno-oncology therapies deal appeared first on Pharmaceutical Business review.

Read more
https://captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2020-02-25 23:31:102020-02-26 00:31:12Genentech, Bicycle Therapeutics sign

immuno-oncology therapies deal

Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC

02/25/2020/0 Comments/in News /by CAPTIS

As per the supplemental New Drug Application (sNDA), the Japanese pharma company is seeking approval of ALUNBRIG for the first-line treatment of patients with anaplastic lymphoma kinase-positive (ALK+) The post Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC appeared first on Pharmaceutical Business review.

Read more
https://captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2020-02-25 04:31:372020-02-25 05:31:39Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC